



Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health
415 N. Washington Street, 2nd Floor
Baltimore, Maryland 21231

6 August 2020

Memorandum

To: Trialists

Fr: Curtis Meinert

Re: The standard trial

Counts by number of treatment groups as registered on CT.gov

Trt groups	All trials registered		Started 2005-09		Started 2015-09	
	No.	%	No.	%	No.	%
1	54,251	26.02	11,754	26.95	19,996	25.41
2	112,524	53.96	22,751	52.17	43,459	55.23
1 or 2	166,775	79.98	34,505	79.12	63,455	80.64
3	23,064	11.06	4,903	11.24	8,635	10.97
4	11,275	5.41	2,568	5.89	3,931	5.00
5	2,891	1.39	710	1.63	955	1.21
3, 4, or 5	37,230	17.86	8,181	18.76	13,521	17.18
6	2,229	1.07	464	1.06	838	1.06
7	631	0.30	152	0.35	207	0.26
8	622	0.30	118	0.27	242	0.31
9	296	0.14	66	0.15	114	0.14
10	220	0.11	43	0.10	79	0.10
11 or more	517	0.25	80	0.19	237	0.30
6 or more	4,515	2.17	923	2.12	1,717	2.17
Total	208,520	100.01	43,609	100	78,693	99.99
Trt groups not reported	84,872	28.93	8,352	16.07	438	0.55

The standard trial, as represented in registrations on CT.gov, is a two treatment group trial. They account for over 50% of all trials done and together with one group trials for 80% of all trials done. There is no evidence the push to do more multi-treatment trials with the hype for platform trials and Bayesian adaptive designs has shifted the field to doing more multi-treatment trials. The percentages of trials with three or more treatment groups for the two time periods examined, basically before and after the push for Bayesian adaptive multi-treatment trials, are the same.